Daniel Baker

7.3k total citations · 2 hit papers
72 papers, 5.2k citations indexed

About

Daniel Baker is a scholar working on Orthopedics and Sports Medicine, Rheumatology and Hematology. According to data from OpenAlex, Daniel Baker has authored 72 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Orthopedics and Sports Medicine, 27 papers in Rheumatology and 19 papers in Hematology. Recurrent topics in Daniel Baker's work include Sports Performance and Training (30 papers), Sports injuries and prevention (21 papers) and Rheumatoid Arthritis Research and Therapies (21 papers). Daniel Baker is often cited by papers focused on Sports Performance and Training (30 papers), Sports injuries and prevention (21 papers) and Rheumatoid Arthritis Research and Therapies (21 papers). Daniel Baker collaborates with scholars based in United States, Australia and Netherlands. Daniel Baker's co-authors include Désirée van der Heijde, Jürgen Braun, Robert Landewé, Pedro Machado, Greg J. Wilson, Robert U. Newton, Michael P. Moore, Tore K Kvien, E. Lie and Xenofon Baraliakos and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Daniel Baker

70 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

2010 549 citations Pedro Machado, Robert Landewé et al. Annals of the Rheumatic Diseases profile →
CAR T therapy beyond cancer: the evolution of a living drug

2023 286 citations Daniel Baker, Zoltàn Arany et al. Nature profile →

Peers

Countries citing papers authored by Daniel Baker

Since Specialization

Citations

This map shows the geographic impact of Daniel Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Baker more than expected).

Fields of papers citing papers by Daniel Baker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Baker. The network helps show where Daniel Baker may publish in the future.

Co-authorship network of co-authors of Daniel Baker

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Baker. A scholar is included among the top collaborators of Daniel Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Baker. Daniel Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases 2024 ·Cell ·Daniel Baker, Carl H. June	12
2	CAR T therapy beyond cancer: the evolution of a living drug breakdown → 2023 ·Nature ·Daniel Baker, Zoltàn Arany, Joseph A. Baur, Jonathan A. Epstein, Carl H. June	286
3	Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial 2013 ·Annals of the Rheumatic Diseases ·Michael E. Weinblatt, René Westhovens, Alan M. Mendelsohn, Lilianne Kim, Kim Hung Lo, Shihong Sheng, Lenore Noonan, Jiandong Lu, Zhenhua Xu, Jocelyn H. Leu, Daniel Baker, Clifton O. Bingham	33
4	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks 2012 ·Annals of the Rheumatic Diseases ·Tsutomu Takeuchi, Masayoshi Harigai, Yoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, Kazuhiko Yamamoto, Nobuyuki Miyasaka, Takao Koike, Minoru Kanazawa, (unknown), Toru Yoshinari, Daniel Baker	49
5	MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor 2012 ·Annals of the Rheumatic Diseases ·Pedro Machado, Robert Landewé, Jürgen Braun, Xenofon Baraliakos, Kay‐Geert Hermann, Benjamin Hsu, Daniel Baker, Désirée van der Heijde	68
6	A stratified model for health outcomes in ankylosing spondylitis 2011 ·Annals of the Rheumatic Diseases ·Pedro Machado, Robert Landewé, Jürgen Braun, Kay‐Geert Hermann, Xenofon Baraliakos, Daniel Baker, Benjamin Hsu, Désirée van der Heijde	60
7	Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty‐eight–week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled study 2010 ·Arthritis & Rheumatism ·Joel M. Kremer, Christopher T. Ritchlin, Alan M. Mendelsohn, Daniel Baker, Lilianne Kim, Zhenhua Xu, John Han, Peter C. Taylor	105
8	German volume training: An alternative method of high volume-load training for stimulating muscle growth 2009 ·Australasian Journal of Paramedicine ·Daniel Baker	4
9	Bonding ability evaluation of bone cement on the cortical surface of rabbit’s tibia 2009 ·Journal of Materials Science Materials in Medicine ·Koji Goto, Keiichi Kawanabe, R. Kowalski, Daniel Baker, Takashi Nakamura	7
10	Ustekinumab: Lessons Learned from Targeting Interleukin‐12/23p40 in Immune‐Mediated Diseases 2009 ·Annals of the New York Academy of Sciences ·Michael R. Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, (unknown), Philippe Szapary	66
11	Comparison of employability outcomes among patients with early or long‐standing rheumatoid arthritis 2008 ·Arthritis Care & Research ·Chenglong Han, Josef S Smolen, Arthur Kavanaugh, E. William St. Clair, Daniel Baker, Mohan Bala	34
12	Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis 2008 ·Arthritis & Rheumatism ·Désirée van der Heijde, Robert Landewé, Xenofon Baraliakos, Harry Houben, Astrid van Tubergen, Paul Williamson, Weichun Xu, Daniel Baker, Neil Goldstein, Jürgen Braun	380
13	Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis 2007 ·The Journal of Clinical Pharmacology ·Honghui Zhou, Haishan Jang, Roy Fleischmann, Esther Bouman‐Thio, Zhenhua Xu, Joseph C. Marini, Charles Pendley, Qun Jiao, Gopi Shankar, Stanley J. Marciniak, Stanley Cohen, Mahboob U. Rahman, Daniel Baker, Mary Ann Mascelli, Hugh M. Davis, Daniel E. Everitt	149
14	Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab 2007 ·Annals of the Rheumatic Diseases ·Sudha Visvanathan, Carrie Wagner, Joseph C. Marini, Daniel Baker, Timothy Gathany, John Han, Désirée van der Heijde, Jürgen Braun	111
15	Double-blinded infliximab dose escalation in patients with rheumatoid arthritis 2007 ·Annals of the Rheumatic Diseases ·(unknown), Ingrid Strusberg, Piet Geusens, (unknown), David E. Yocum, Daniel Baker, Carrie Wagner, John Han, René Westhovens	91
16	The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases 2007 ·Arthritis Research & Therapy ·Chenglong Han, Josef S Smolen, Arthur Kavanaugh, Désirée van der Heijde, Jürgen Braun, René Westhovens, Ning Zhao, Mahboob U. Rahman, Daniel Baker, Mohan Bala	38
17	Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial 2006 ·Arthritis & Rheumatism ·Josef S Smolen, Désirée van der Heijde, E. William St. Clair, Paul Emery, Joan M. Bathon, Edward Keystone, Ravinder N. Maini, Joachim R. Kalden, Michael Schiff, Daniel Baker, Chenglong Han, John Han, Mohan Bala, (unknown)	342
18	IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis 2006 ·Arthritis & Rheumatism ·Sudha Visvanathan, Carrie Wagner, Josef S Smolen, E. William St. Clair, (unknown), Daniel Baker, Gregory F. Keenan	8
19	Acute Negative Effect of a Hypertrophy-Oriented Training Bout on Subsequent Upper-Body Power Output 2003 ·The Journal of Strength and Conditioning Research ·Daniel Baker	18
20	The Relation Between Strength and Power in Professional Rugby League Players 1999 ·The Journal of Strength and Conditioning Research ·Daniel Baker, (unknown)	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact